Literature DB >> 32268133

Hepatitis C virus infection and tight junction proteins: The ties that bind.

Laurent Mailly1, Thomas F Baumert2.   

Abstract

The hepatitis C virus (HCV) is a major cause of liver diseases ranging from liver inflammation to advanced liver diseases like cirrhosis and hepatocellular carcinoma (HCC). HCV infection is restricted to the liver, and more specifically to hepatocytes, which represent around 80% of liver cells. The mechanism of HCV entry in human hepatocytes has been extensively investigated since the discovery of the virus 30 years ago. The entry mechanism is a multi-step process relying on several host factors including heparan sulfate proteoglycan (HSPG), low density lipoprotein receptor (LDLR), tetraspanin CD81, Scavenger Receptor class B type I (SR-BI), Epidermal Growth Factor Receptor (EGFR) and Niemann-Pick C1-like 1 (NPC1L1). Moreover, in order to establish a persistent infection, HCV entry is dependent on the presence of tight junction (TJ) proteins Claudin-1 (CLDN1) and Occludin (OCLN). In the liver, tight junction proteins play a role in architecture and homeostasis including sealing the apical pole of adjacent cells to form bile canaliculi and separating the basolateral domain drained by sinusoidal blood flow. In this review, we will highlight the role of liver tight junction proteins in HCV infection, and we will discuss the potential targeted therapeutic approaches to improve virus eradication.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Claudin-1; Hepatitis C virus; Occludin; Tight junctions; Viral entry and spreading

Mesh:

Substances:

Year:  2020        PMID: 32268133      PMCID: PMC7613427          DOI: 10.1016/j.bbamem.2020.183296

Source DB:  PubMed          Journal:  Biochim Biophys Acta Biomembr        ISSN: 0005-2736            Impact factor:   4.019


  158 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Gene expression of the tight junction protein occludin includes differential splicing and alternative promoter usage.

Authors:  Joachim Mankertz; Jörg Stefan Waller; Bernd Hillenbrand; Shida Tavalali; Peter Florian; Torsten Schöneberg; Michael Fromm; Jörg Dieter Schulzke
Journal:  Biochem Biophys Res Commun       Date:  2002-11-15       Impact factor: 3.575

3.  Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection.

Authors:  Yoshimi Shimizu; Kohei Yoneda; Yoshitaka Shirasago; Takeru Suzuki; Minoru Tada; Akiko Ishii-Watabe; Kazuo Sugiyama; Tetsuro Suzuki; Takaji Wakita; Kiyohito Yagi; Masuo Kondoh; Masayoshi Fukasawa
Journal:  Biochem Biophys Res Commun       Date:  2019-05-09       Impact factor: 3.575

4.  Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.

Authors:  A Higginbottom; E R Quinn; C C Kuo; M Flint; L H Wilson; E Bianchi; A Nicosia; P N Monk; J A McKeating; S Levy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy.

Authors:  U P Neumann; M Biermer; D Eurich; P Neuhaus; T Berg
Journal:  J Hepatol       Date:  2010-03-15       Impact factor: 25.083

6.  A key claudin extracellular loop domain is critical for epithelial barrier integrity.

Authors:  Randall J Mrsny; G Thomas Brown; Kirsten Gerner-Smidt; Andre G Buret; Jon B Meddings; Clifford Quan; Michael Koval; Asma Nusrat
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

7.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Peter Richardson; Jennifer Kramer
Journal:  Hepatology       Date:  2016-04-19       Impact factor: 17.425

8.  Occludin-Knockout Human Hepatic Huh7.5.1-8-Derived Cells Are Completely Resistant to Hepatitis C Virus Infection.

Authors:  Yoshitaka Shirasago; Yoshimi Shimizu; Isei Tanida; Tetsuro Suzuki; Ryosuke Suzuki; Kazuo Sugiyama; Takaji Wakita; Kentaro Hanada; Kiyohito Yagi; Masuo Kondoh; Masayoshi Fukasawa
Journal:  Biol Pharm Bull       Date:  2016-02-17       Impact factor: 2.233

Review 9.  The role of microtubules in the regulation of epithelial junctions.

Authors:  Ekaterina Vasileva; Sandra Citi
Journal:  Tissue Barriers       Date:  2018-11-05

10.  Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles.

Authors:  Jieyun Jiang; Guangxiang Luo
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

View more
  3 in total

Review 1.  TM4SF5-Mediated Regulation of Hepatocyte Transporters during Metabolic Liver Diseases.

Authors:  Ji Eon Kim; Eunmi Kim; Jung Weon Lee
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

Review 2.  ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment.

Authors:  Nathalie Théret; Fidaa Bouezzedine; Fida Azar; Mona Diab-Assaf; Vincent Legagneux
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

Review 3.  Virus interactions with the actin cytoskeleton-what we know and do not know about SARS-CoV-2.

Authors:  Malgorzata Kloc; Ahmed Uosef; Jarek Wosik; Jacek Z Kubiak; Rafik M Ghobrial
Journal:  Arch Virol       Date:  2022-01-31       Impact factor: 2.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.